Pembrolizumab is a monoclonal IgG4 antibody directed against PD-1, which blocks the immunosuppression mediated by the interaction of PD-L1 on tumor cells and PD-1 on CD8+ and CD4+ T cells, therefore, improving tumor cell recognition by T cells [36, 40, 49]. Here, PDCD1 is linked to neoplasm.